Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

Lophius Biosciences Performs Successful Clinical Validation for T-Track® CMV/EBV Test Systems

Published: Thursday, April 26, 2012
Last Updated: Wednesday, April 25, 2012
Bookmark and Share
Both systems aim to increase transplantation outcome and reduce negative therapeutic effects.

Lophius Biosciences has announced the successful completion of a prospective multicenter clinical validation study for its T-Track® CMV/EBV tests.

In cooperation with four dialysis centers in Germany (Regensburg, Mannheim, Straubing and Landshut) the ability of both T-Track® CMV/EBV tests with respect to determination of functional effector cells of cell-mediated immunity was successfully examined during 4th quarter 2011 in a cohort of > 120 hemodialysis patients.

Using standard statistical analysis tools, the clinical sensitivities were 100% for T-Track® CMV and 97% for T-Track® EBV in this cohort.

Based on the study results Lophius Biosciences was able to develop a novel simple biostatistical method for T-cell based tests, which should allow comparative analysis between different patient groups in the future.

This is a key prerequisite for the use of both T-Track® CMV/EBV tests for a routine immune monitoring. Using this novel tool, clinical sensitivities were 88% for T-Track® CMV and 86% for T-Track® EBV.

“We were very impressed with the high clinical sensitivities for both T-Track® CMV and T-Track ® EBV Tests“, said Prof. Dr. Bernhard Banas, Department Head of Nephrology und Transplantation Center of the University Hospital Regensburg.

Prof. Banas continued, “In connection with its high degree of standardization, both test systems may be key for a personalized therapy in transplantation medicine, with the aim to increase transplantation outcome and reduce negative therapeutic effects”.

“We are delighted that we were able as part of the validation study to develop an analysis tool for the first time that may set the basis for a standardized measurement of cell-mediated immune response. This should allow a user-friendly monitoring of the immune status of immune compromized patients e.g. after transplantation, but also in other indications” added PD Dr. Ludwig Deml, CSO of Lophius Biosciences.

Dr. Michael Lutz, CEO of Lophius Biosciences, said: “The successful completion of both test developments for both T-Track® CMV and T-Track® EBV tests in a short timeframe underpins the high innovative potential of our proprietary technology platform. This could set the basis for novel T-cell based diagnostic systems in areas with high medical need”.

Lophius Biosciences will present the study results at the world biggest transplantation conference (TTS) in Berlin in July 2012.

Moreover, the company aims to publish the study results as quickly as possible in a leading scientific journal.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,700+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Lophius Biosciences Appoints Dr. Robert Phelps as Director Business Operations
Dr. Phelps has longstanding experience in business development and licensing.
Wednesday, December 04, 2013
Lophius Biosciences Joins NEU² Program
Company receives substantial grant funding for the diagnosis and monitoring of multiple sclerosis.
Wednesday, June 19, 2013
Lophius Biosciences Closes Financing Round and Expands Management Board
Lophius Biosciences announces the closing of a further financing round with Prof. Dr Ralf Wagner been appointed as Managing Director.
Tuesday, January 22, 2013
Lophius Biosciences Concludes TB Detection Trials
Company achieves first clinical Proof of Principle for T-Track® TB for detection of active tuberculosis and receives research funding.
Thursday, November 08, 2012
Lophius Biosciences Completes Necessary Regulatory Milestones with EN ISO 13485 Certification
Company has received CE-marking for its T-Track® CMV and T-Track® EBV tests.
Friday, June 01, 2012
Lophius Biosciences Closes Additional Financing Round with Current Investors Totaling 1.4 Million EUR
Financial investors such as S-Refit, High-Tech Gründerfonds and Bayernkapital participated in this financing round.
Tuesday, July 19, 2011
Lophius Biosciences Expands its Management Team and Prepares for Market Entry at the Beginning of 2012
The team is completed by Dr. Zanker from MedicalDevice+, an experienced expert in the field of regulatory affairs for diagnostic products.
Tuesday, July 12, 2011
Scientific News
Education and Expense: The Barriers to Mass Spectrometry in Clinical Laboratories?
Here we examine the perceived barriers to mass spec in clinical laboratories and explore the possible drivers behind the recent shift in uptake of the technology in clinical settings.
Adult High Blood Pressure Risk Identifiable in Childhood
Groups of people at risk of having high blood pressure and other related health issues by age 38 can be identified in childhood, new University of Otago research suggests.
Potential New Diagnosis and Therapy for Breast Cancer
Scientists at the University of York, using clinical specimens from charity Breast Cancer Now’s Tissue Bank, have conducted new research into a specific sodium channel that indicates the presence of cancer cells and affects tumour growth rates.
Paving the Way for Diamonds to Trace Early Cancers
Researchers from the University of Sydney reveal how nanoscale 'diamonds' can light up early-stage cancers in MRI scans.
Will Brain Palpation Soon Be Possible?
Researchers have developed non-invasive brain imaging technique which provides the same information as physical palpation.
Groundbreaking Computer Program Diagnoses Cancer in Two Days
Researchers have combined genetics with computer science and created a new diagnostic technology can with 85 per cent certainty identify the source of the disease and thus target treatment and, ultimately, improve the prognosis for the patient.
Detecting HIV Diagnostic Antibodies with DNA Nanomachines
New research may revolutionize the slow, cumbersome and expensive process of detecting the antibodies that can help with the diagnosis of infectious and auto-immune diseases such as rheumatoid arthritis and HIV.
Horse Illness Shares Signs of Human Disease
Horses with a rare nerve condition have similar signs of disease as people with conditions such as Alzheimer’s, a study has found.
Compound Doubles Up On Cancer Detection
Researchers have found that tagging a pair of markers found almost exclusively on a common brain cancer yields a cancer signal that is both more obvious and more specific to cancer.
The Age of Humans Controlling Microbes
Engineered bacteria could soon be used to detect environmental toxins, treat diseases, and sustainably produce chemicals and fuels.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,700+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos